Navigation Links
Newly Released Canadian Data Links Vaccines with Pervasive,Developmental Disorder

National Autism Association calls 2006 Pediatrics study fatally flawed

CHICAGO, March 07, 2007 /PRNewswire-USNewswire/ -- New findings presented yesterday at a National Autism Association meeting bolster claims that vaccines may play a role in the development of autism spectrum disorders. David Ayoub, MD presented data suggesting a correlation between mercury- containing vaccines and rates of pervasive developmental disorder (PDD), a form of autism, in Montreal. The peak rate of one in 87 children diagnosed with PDD occurred following the period of greatest exposure to the mercury- based vaccine preservative thimerosal. A flattening of the rates studied is now emerging as mercury-containing vaccines have been gradually eliminated from the routine schedule.

This new data points out flaws in a 2006 study published in the journal Pediatrics by Eric Fombonne, MD, et al, which found PDD rates continued to increase even when rates of MMR vaccination and use of mercury-containing vaccines decreased. The study population consisted of a single Montreal school board that was an Autism Center of Excellence, suggesting an over- ascertainment of regional diagnoses. Dr. Ayoub and co-authors Monica Ruscitti, BA, and F. Edward Yazbak, MD broadened the data to include all five Montreal school boards.

The earlier study also reported PDD rates in children from Montreal, but MMR coverage data was taken from Quebec City located 265km from Montreal. The researchers confirmed MMR coverage rates actually increased in Montreal along with PDD, noting a sharper rise in rates after the number of required MMR shots doubled.

The Pediatrics paper claimed there was no exposure to mercury from vaccines post-1996 although several mercury-containing vaccines were administered well beyond 1996. "It's irresponsible that such flawed data was published in a medical journal. This new information confirms a relationship between va ccines and autism that can't be explained by better diagnosing or changing diagnostic criteria," said Karen McDonough, NAA -- Chicago president.

Drs. Ayoub and Yazbak detailed the Fombonne study flaws in letters to Pediatrics which the journal declined to publish. Editor Jerold F. Lucey, MD stated in a reply, "I believe the evidence of no link between MMR and Autism is sufficient. It's not worth publishing more on this subject."

"This dismissal of legitimate concerns regarding data affecting those suffering with autism is a disgrace," commented Ms. McDonough.

     For more information:  www.nationalautism.org


     Contacts:  Wendy Fournier 401-632-7523

                Rita Shreffler 417-818-9030

CONTACT: Wendy Fournier, +1-401-632-7523, or Rita Shreffler,+1-417-818-9030, both of National Autism Association

Web site: http://www.nationalautism.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in the safety of your ... drownings during the summer. While most of us assume this type of accident will ... Very few people are taking the time to learn how to respond effectively or ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... announce the ATA 2017 President’s Awards recipients, comprised of organizations and individuals ... delivery. , The ATA 2017 President’s Awards recognize individuals and organizations ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... ecosystem and domain expertise for sponsors and CROs to speed clinical development, ... management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor ... I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded ...
Breaking Medicine News(10 mins):